Therapeutic monoclonal antibodies in ophthalmology

Progress in Retinal and Eye Research

Volumn 28, Issue 2, 2009, Pages 117-144

  Rodrigues, Eduardo B ^a   Farah, Michel E ^a   Maia, Maurício ^a   Penha, Fernando M ^a   Regatieri, Caio ^a   Melo, Gustavo B ^a   Pinheiro, Marcelo M ^a   Zanetti, Carlos R ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Avastin; Bevacizumab; Eye; Lucentis; Monoclonal antibodies; Ranibizumab; Retina; Tumor necrosis factor; Vascular endothelial growth factor

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; CORTICOSTEROID; DACLIZUMAB; DEXAMETHASONE; ECULIZUMAB; EFALIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ETANERCEPT; FLUOROURACIL; INFLIXIMAB; IRINOTECAN; LERDELIMUMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PANITUMUMAB; PLACEBO; RANIBIZUMAB; RITUXICAN; RITUXIMAB; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VERTEPORFIN;

AMPUTATION; ANEURYSM; ANGIOGENESIS; ANKYLOSING SPONDYLITIS; ANTIBODY PRODUCTION; ANTIBODY STRUCTURE; ARTHRALGIA; ATOPIC DERMATITIS; B CELL LYMPHOMA; BACKACHE; BEHCET DISEASE; BLEEDING; BLOOD PRESSURE; BLOOD TOXICITY; BREAST CANCER; CATARACT; CELLULITIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; COMMON COLD SYMPTOM; CONGESTIVE HEART FAILURE; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVITIS; CONSTIPATION; CROHN DISEASE; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; ECTROPION; ENDOPHTHALMITIS; EYE DISEASE; EYE EDEMA; EYE INFLAMMATION; EYE PAIN; FEVER; GLAUCOMA; HEADACHE; HEART INFARCTION; HERPES; HUMAN; HYPEREMIA; HYPERTENSION; HYPOTENSION; INGUINAL HERNIA; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY CANCER; KIDNEY FIBROSIS; LEUKEMIA; LEUKOENCEPHALOPATHY; LUNG CANCER; LUNG EMBOLISM; LUPUS LIKE SYNDROME; LYMPHOMA; MALAISE; MYELOMA; NAUSEA; NONHUMAN; OPHTHALMOPLEGIA; OPTIC NERVE DISEASE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEINURIA; PRURITUS; PSORIASIS; RASH; REPEATED DRUG DOSE; RESPIRATORY TRACT INFECTION; RETINA DETACHMENT; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; STROKE; SWELLING; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TUBERCULOSIS; TUBULOINTERSTITIAL FIBROSIS; UVEITIS; VITREITIS; VITREOUS DISEASE; VITREOUS HEMORRHAGE; VOMITING; WEGENER GRANULOMATOSIS; WOUND HEALING IMPAIRMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; EYE DISEASES; HUMANS; IMMUNOGLOBULIN G; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 59849110597     PISSN: 13509462     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2008.11.005     Document Type: Review

References (272)

1. Abu El-Asrar A.M., Abboud E.B., Aldibhi H., and Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behcet's disease. Int. Ophthalmol. 26 (2005) 83-92
2. Adán A., Mateo C., Navarro R., Bitrian E., and Casaroli-Marano R.P. Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 27 (2007) 1180-1186
3. Ahmad T., Wallace G.R., James T., Neville M., Bunce M., Mulcahy-Hawes K., Armuzzi A., Crawshaw J., Fortune F., Walton R., Stanford M.R., Welsh K.I., Marshall S.E., and Jewell D.P. Mapping the HLA association in Behçet's disease: a role for tumor necrosis factor polymorphisms?. Arthritis Rheum. 48 (2003) 807-813
4. Andersen D.C., and Reilly D.E. Production technologies for monoclonal antibodies and their fragments. Curr. Opin. Biotechnol. 15 (2004) 456-462
5. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331 (1994) 1480-1487
6. Aiello L.P., Pierce E.A., Foley E.D., Takagi H., Chen H., Riddle L., Ferrara N., King G.L., and Smith L.E. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 10457-10461
7. Arevalo, J.F., Wu, L., Sanchez, J.G., Maia, M., Saravia, M.J., Fernandez, C.F., Evans, T., Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye, in press.
8. Arevalo J.F., Maia M., Flynn Jr. H., Saravia M., Avery R.L., Wu L., Eid Farah M., Pieramici D.J., Berrocal M.H., and Sanchez J.G. Tractional retinal detachment following intravitreal bevacizumab (Avastin(R)) in patients with severe proliferative diabetic retinopathy. Br. J. Ophthalmol. 92 (2008) 213-216
9. Ashok D., Ayliffe W.H., and Kiely P.D. Necrotizing scleritis associated with rheumatoid arthritis: long-term remission with high-dose infliximab therapy. Rheumatology 44 (2005) 950-951
10. Avery R.L., Pearlman J., Pieramici D.J., Rabena M.D., Castellarin A.A., Nasir M.A., Giust M.J., Wendel R., and Patel A. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113 (2006) 1695 e1-e15
11. Avunduk M.C., Avunduk A.M., Oztekin E., Oztekin E., Baltaci A.K., Ozyazgan Y., and Mogolkoc R. Etanercept treatment in the endotoxin-induced uveitis of rats. Exp. Eye Res. 79 (2004) 357-365
12. Bakri S.J., Snyder M.R., Reid J.M., Pulido J.S., Ezzat M.K., and Singh R.J. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114 (2007) 2179-2182
13. Bakri S.J., Snyder M.R., Reid J.M., Pulido J.S., and Singh R.J. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114 (2007) 855-859
14. Bashshur Z.F., Bazarbachi A., Schakal A., Haddad Z.A., El Haibi C.P., and Noureddin B.N. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am. J. Ophthalmol. 142 (2006) 1-9
15. Bashshur Z.F., Haddad Z.A., Schakal A., Jaafar R.F., Saab M., and Noureddin B.N. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am. J. Ophthalmol. 145 (2008) 249-256
16. Baughman R.P., Bradley D.A., and Lower E.E. Infliximab in chronic ocular inflammation. Int. J. Clin. Pharmacol. Ther. 43 (2005) 7-11
17. Bellomo D., Headrick J.P., Silins G.U., Paterson C.A., Thomas P.S., Gartside M., Mould A., Cahill M.M., Tonks I.D., Grimmond S.M., Townson S., Wells C., Little M., Cummings M.C., Hayward N.K., and Kay G.F. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ. Res. 86 (2000) E29-E35
18. Benitez-del-Castillo J.M., Martinez-de-la-Casa J.M., Pato-Cour E., Pato-Courm E., Méndez-Fernández R., López-Abad C., Matilla M., and Garcia-Sanchez J. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye 19 (2005) 841-845
19. Bergers G., Song S., Meyer-Morse N., Bersland E., and Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Investig. 111 (2003) 1287-1295
20. Bhisitkul R.B. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br. J. Ophthalmol. 90 (2006) 1542-1547
21. Biester S., Deuter C., Michels H., Haefner R., Kuemmerle-Deschner J., Doycheva D., and Zierhut M. Adalimumab in the therapy of uveitis in childhood. Br. J. Ophthalmol. 91 (2007) 319-324
22. Blaauwgeers H.G., Holtkamp G.M., Rutten H., Witmer A.N., Koolwijk P., Partanen T.A., Alitalo K., Kroon M.E., Kijlstra A., van Hinsbergh V.W., and Schlingemann R.O. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am. J. Pathol. 155 (1999) 421-428
23. Bock F., Onderka J., Dietrich T., Bachmann B., Kruse F.E., Paschke M., Zahn G., and Cursiefen C. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Investig. Ophthalmol. Vis. Sci. 48 (2007) 2545-2552
24. Bodaghi B., Bui Quoc E., Wechsler B., Tran T.H., Cassoux N., Le Thi Huong D., Chosidow O., Herson S., Piette J.C., and LeHoang P. Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann. Rheum. Dis. 64 (2005) 962-964
25. Boyd S.R., Tan D.S., de Souza L., Neale M.H., Myatt N.E., Alexander R.A., Robb M., Hungerford J.L., and Cree I.A. Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth. Br. J. Ophthalmol. 86 (2002) 440-447
26. Braun J., Baraliakos X., Listing J., and Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 52 (2005) 2447-2451
27. Byeon S.H., Kwon Y.A., Oh H.S., Kim M., and Kwon O.W. Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema. J. Ocul. Pharmacol. Ther. 23 (2007) 387-394
28. Byrne A.M., Bouchier-Hayes D.J., and Harmey J.H. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J. Cell Mol. Med. 9 (2005) 777-794
29. Cahalan M.D., and Gutman G.A. The sense of place in the immune system. Nat. Immunol. 7 (2006) 329-332
30. Calabrese L.H. Molecular differences in anticytokine therapies. Clin. Exp. Rheumatol. 21 (2003) 241-248
31. Caldwell R.B., Bartoli M., Behzadian M.A., El-Remessy A.E., Al-Shabrawey M., Platt D.H., and Caldwell R.W. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab. Res. Rev. 19 (2003) 442-455
32. Campochiaro P.A. Ocular neovascularisation and excessive vascular permeability. Expert Opin. Biol. Ther. 4 (2004) 1395-1402
33. Campochiaro P.A. Ocular versus extraocular neovascularization: mirror images or vague resemblances. Invest. Ophthalmol. Vis. Sci. 47 (2006) 462-474
34. Campochiaro P.A. Molecular targets for retinal vascular diseases. J. Cell Physiol. 210 (2007) 575-581
35. Campochiaro P.A. Targeted pharmacotherapy of retinal diseases with ranibizumab. Drugs Today (Barc) 43 (2007) 529-537
36. Campochiaro P.A. Seeing the light: new insights into the molecular pathogenesis of retinal diseases. J. Cell Physiol. 213 (2007) 348-354
37. Campochiaro P.A., and Glaser B.M. Platelet-derived growth factor is chemotactic for human retinal pigment epithelial cells. Arch. Ophthalmol. 103 (1985) 576-579
38. CAT-152 0102 Trabeculectomy Study Group, Khaw P., Grehn F., et al. A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology 114 (2007) 1822-1830
39. Cazabon S., Over K., and Butcher J. The successful use of infliximab in resistant relapsing polychondritis and associated scleritis. Eye 19 (2005) 222-224
40. Chamberlain C.G., and McAvoy J.W. Evidence that fibroblast growth factor promotes lens fibre differentiation. Curr. Eye. Res. 6 (1987) 1165-1169
41. Chan C.K., Meyer C.H., Gross J.G., Abraham P., Nuthi A.S., Kokame G.T., Lin S.G., Rauser M.E., and Kaiser P.K. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 27 (2007) 541-551
42. Chen G., and Goeddel D.V. TNF-R1 signaling: a beautiful pathway. Science 296 (2002) 1634-1635
43. Chung J.H., Van Stavern G.P., Frohman L.P., and Turbin R.E. Adalimumab-associated optic neuritis. J. Neurol. Sci. 15 (2006) 133-136
44. Coiffer B. Rituximab therapy in malignant lymphoma. Oncogene 26 (2007) 3603-3613
45. Conti F., Priori R., Chimenti M.S., Coari G., Annovazzi A., Valesini G., and Signore A. Successful treatment with intraarticular infliximab for resistant knee monoarthritis in a patient with spondyloarthropathy: a role for scintigraphy with 99mTc-infliximab. Arthritis Rheum. 52 (2005) 1224-1226
46. Cunningham Jr. E.T., Stalder A., Sanna P.P., Liu S.S., Bloom F.E., Howes Jr. E.L., Campbell I.L., and Margolis T.P. Localization of tumor necrosis factor receptor messenger RNA in normal and herpes simplex virus-infected mouse eyes. Investig. Ophthalmol. Vis. Sci. 38 (1997) 9-15
47. D'Alessandro A.M., Pirsch J.D., Stratta R.J., Sollinger H.W., Kalayoglu M., Maki D.G., and Belzer F.O. OKT3 salvage therapy in a quadruple immunosuppressive protocol in cadaveric renal transplantation. Transplantation 47 (1989) 297-300
48. Deissler H., Deissler H., Lang S., and Lang G.E. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells. Br. J. Ophthalmol. 92 (2008) 839-843
49. Derevjanik N.L., Vinores S.A., Xiao W.H., Mori K., Turon T., Hudish T., Dong S., and Campochiaro P.A. Quantitative assessment of the integrity of the blood-retinal barrier in mice. Investig. Ophthalmol. Vis. Sci. 43 (2002) 2462-2467
50. Deuter C.M., Kötter I., Wallace G.R., Murray P.I., Stübiger N., and Zierhut M. Behçet's disease: ocular effects and treatment. Prog. Retin. Eye Res (Nov 20, 2007)
51. Diabetic Retinopathy Clinical Research Network, Scott I.U., Edwards A.R., Beck R.W., Bressler N.M., Chan C.K., Elman M.J., Friedman S.M., Greven C.M., Maturi R.K., Pieramici D.J., Shami M., Singerman L.J., and Stockdale C.R. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114 (2007) 1860-1867
52. Diaz-Valle D., Miguelez Sanchez R., Fernández Espartero M.C., and Pascual Allen D. Treatment of refractory anterior diffuse scleritis with infliximab. Arch. Soc. Esp. Oftalmol. 79 (2004) 405-408
53. Dick A.D., Forrester J.V., Liversidge J., and Cope A.P. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog. Retin. Eye Res. 23 (2004) 617-637
54. Dick A.D., Meyer P., James T., Forrester J.V., Hale G., Waldmann H., and Isaacs J.D. Campath-1H therapy in refractory ocular inflammatory disease. Br. J. Ophthalmol. 84 (2000) 107-109
55. Doganay S., Evereklioglu C., Er H., Türköz Y., Sevinç A., Mehmet N., and Savli H. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye 16 (2002) 163-170
56. Duh E., and Aiello L.P. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 48 (1999) 1899-1906
57. Durrani O.M., Reuser T.Q., and Murray P.I. Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit 24 (2005) 117-119
58. Edrees A.F., Misra S.N., and Abdou N.I. Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin. Exp. Rheumatol. 23 (2005) 469-474
59. Ehlers J.P., Spirn M.J., Lam A., Sivalingam A., Samuel M.A., and Tasman W. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina 28 (2008) 696-702
60. Eliceiri B.P., Paul R., Schwartzberg P.L., Hood J.D., Leng J., and Cheresh D.A. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 4 (1999) 915-924
61. El-Shabrawi Y., and Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 109 (2002) 2342-2346
62. El-Shabrawi Y., and Hermann J. Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener's granulomatosis. Eye 19 (2005) 1017-1018
63. Eriksson U., and Alitalo K. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr. Top. Microbiol. Immunol 237 (1999) 41-57
64. Ettinger R., Mebius R., Browning J.L., Michie S.A., van Tuijl S., Kraal G., van Ewijk W., and McDevitt H.O. Effects of tumor necrosis factor and lymphotoxin on peripheral lymphoid tissue development. Int. Immunol. 10 (1998) 727-741
65. Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Surv. Ophthalmol. 50 (2005) 297-350
66. Falappone P.C., Iannone F., Scioscia C., Grattagliano V., Covelli M., and Lapadula G. The treatment of recurrent uveitis with TNF-alpha inhibitors. Reumatismo 56 (2004) 185-189
67. Fauser S., Kalbacher H., Alteheld N., Koizumi K., Krohne T.U., and Joussen A.M. Pharmacokinetics and safety of intravitreally delivered etanercept. Graefes Arch. Clin. Exp. Ophthalmol. 242 (2004) 582-586
68. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 280 (2001) 1358-1366
69. Ferrara N., Damico L., Shams N., Lowman H., and Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26 (2006) 859-870
70. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptor. Nat. Med. 9 (2003) 669-676
71. Ferrara D.C., Koizumi H., and Spaide R.F. Early bevacizumab treatment of central retinal vein occlusion. Am. J. Ophthalmol. 144 (2007) 864-871
72. Foeldvari I., Nielsen S., Kummerle-Deschner J., Espada G., Horneff G., Bica B., Olivieri A.N., Wierk A., and Saurenmann R.K. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J. Rheumatol. 34 (2007) 1146-1150
73. Fontaine V., Mohand-Said S., Hanoteau N., Fuchs C., Pfizenmaier K., and Eisel U. Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J. Neurosci. 22 (2002) 216
74. Foote J. Immunology: isomeric antibodies. Science 299 (2003) 1327-1328
75. Foster C.S., Tufail F., Waheed N.K., Chu D., Miserocchi E., Baltatzis S., and Vredeveld C.M. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch. Ophthalmol. 121 (2003) 437-440
76. Friedlander S.M., and Welch R.M. Vanishing disc neovascularization following intravitreal bevacizumab (avastin) injection. Arch. Ophthalmol. 124 (2006) 1365
77. Fung A.E., Rosenfeld P.J., and Reichel E. The international Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br. J. Ophthalmol. 90 (2006) 1344-1349
78. Furst D.E., Schiff M.H., Fleischmann R.M., Strand V., Birbara C.A., Compagnone D., Fischkoff S.A., and Chartash E.K. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 30 (2003) 2563-2571
79. Furst D.E., Wallis R., Broder M., and Beenhouwer D.O. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum. 36 (2006) 159-167
80. Galor A., Perez V.L., Hammel J.P., and Lowder C.Y. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 113 (2006) 2317-2323
81. Gardiner T.A., Gibson D.S., de Gooyer T.E., de la Cruz V.F., McDonald D.M., and Stitt A.W. Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy. Am. J. Pathol. 166 (2005) 637-644
82. Gardreault J., Fei D., Rusit J., Suboc P., and Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Investig. Ophthalmol. Vis. Sci. 46 (2005) 726-733
83. Garrity J.A., Coleman A.W., Matteson E.L., Eggenberger E.R., and Waitzman D.M. Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. Am. J. Ophthalmol. 138 (2004) 925-930
84. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., and Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273 (1998) 30336-30343
85. Giansanti F., Barbera M.L., Virgili G., Pieri B., Emmi L., and Menchini U. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behcet disease. Eur. J. Ophthalmol. 14 (2004) 445-448
86. Giansanti F., Ramazzotti M., Vannozzi L., Rapizzi E., Fiore T., Iaccheri B., Degl' Innocenti D., Moncini D., and Menchini U. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Investig. Ophthalmol. Vis. Sci. 49 (2008) 1151-1156
87. Gillies M.C., and Wong T.Y. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 356 (2007) 748-749
88. Goldstein G., Fuccello A.J., Norman D.J., Shield III C.F., Colvin R.B., and Cosimi A.B. OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation 42 (1986) 507-511
89. Grant M.B., Afzal A., Spoerri P., Pan H., Shaw L.C., and Mames R.N. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin. Investig. Drugs 13 (2004) 1275-1293
90. Greiner K., Murphy C.C., Willermain F., Duncan L., Plskova J., Hale G., Isaacs J.D., Forrester J.V., and Dick A.D. Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Investig. Ophthalmol. Vis. Sci. 45 (2004) 170-176
91. Gündüz K., Pulido J.S., McCannel C.A., and O'Neill B.P. Ocular manifestations and treatment of central nervous system lymphomas. Neurosurg. Focus 21 (2006) E9
92. Hale S., and Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 33 (2006) 231-237
93. Hampton T. Monoclonal antibody therapies shine in breast cancer clinical trials. JAMA 293 (2005) 2985-2989
94. Hangai M., He S., Hoffmann S., Lim J.I., Ryan S.J., and Hinton D.R. Sequential induction of angiogenic growth factors by TNF-alpha in choroidal endothelial cells. J. Neuroimmunol. 171 (2006) 45-56
95. Haritoglou C., Kook D., Neubauer A., Wolf A., Priglinger S., Strauss R., Gandorfer A., Ulbig M., and Kampik A. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26 (2006) 999-1005
96. Hehlgans T., and Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115 (2005) 1-20
97. Heidenkummer H.P., and Kampik A. Immunohistochemical localization of epidermal growth factor receptor in a human epirtinal membrane. Graefes Arch. Clin. Exp. Ophthalmol. 229 (1991) 492-496
98. Heiduschka P., Fietz H., Hofmeister S., Schultheiss S., Mack A.F., Peters S., Ziemssen F., Niggemann B., Julien S., Bartz-Schmidt K.U., Schraermeyer U., and Tübingen Bevacizumab Study Group. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Investig. Ophthalmol. Vis. Sci. 48 (2007) 2814-2823
99. Hernández-Rojas M.L., Quiroz-Mercado H., Dalma-Weiszhausz J., Fromow-Guerra J., Amaya-Espinosa A., Solís-Vivanco A., Reyna-Castelán E., Abraham-Marín M., Martínez-Castellanos M.A., and Aiello L.P. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 27 (2007) 707-712
100. Horn W., and Hoerauf H. Intravitreal injections during anticoagulant treatment. Klin. Monatsbl. Augenheilkd. 225 (2008) 217-219
101. Holliger P., and Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23 (2005) 1126-1136
102. Homsi J., and Daud A.I. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 14 (2007) 285-294
103. Honda S., Hirabayashi H., Tsukahara Y., and Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch. Clin. Exp. Ophthalmol. (Mar 5, 2008)
104. Hurmeric V., Mumcuoglu T., Erdurman C., Kurt B., Dagli O., and Durukan A.H. Effect of subconjunctival bevacizumab (avastin) on experimental corneal neovascularization in Guinea pigs. Cornea 27 (2008) 357-362
105. Hwang W.Y., and Foote J. Immunogenicity of engineered antibodies. Methods 36 (2005) 3-10
106. Imanishi J., Kamiyama K., Iguchi I., Kita M., Sotozono C., and Kinoshita S. Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog. Retin. Eye Res. 19 (2000) 113-129
107. Imrie F.R., and Dick A.D. Biologics in the treatment of uveitis. Curr. Opin. Ophthalmol. 18 (2007) 481-486
108. Inan U.U., Avci B., Kusbeci T., Kaderli B., Avci R., and Temel S.G. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Investig. Ophthalmol. Vis. Sci. 48 (2007) 1773-1781
109. Iriyama A., Chen Y.N., Tamaki Y., and Yanagi Y. Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br. J. Ophthalmol. 91 (2007) 1230-1233
110. Jin K.L., Mao X.O., and Greenberg D.A. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc. Natl. Acad. Sci. U.S.A. 29 (2000) 10242-10247
111. Johnston S. Designer drugs: the biologic therapies. Clin. Med. 6 (2006) 337-343
112. Jonas J.B., Libondi T., von Baltz S., and Vossmerbaeumer U. Intravitreal bevacizumab for vitreous haemorrhage. Acta Ophthalmol. Scand. (Dec 12, 2007)
113. Jones P.T., Dear P.H., Foote J., Neuberger M.S., and Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321 (1986) 522-525
114. Joseph A., Raj D., Dua H.S., Powell P.T., Lanyon P.C., and Powell R.J. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 110 (2003) 1449-1453
115. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., Saksela O., Kalkkinen N., and Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO. J. 15 (1996) 290-298
116. Kahn P., Weiss M., Imundo L.F., and Levy D.M. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 113 (2006) 1-2
117. Kaipainen A., Korhonen J., Mustonen T., van Hinsbergh V.W., Fang G.H., Dumont D., Breitman M., and Alitalo K. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 3566-3570
118. Kaiser P.K. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am. J. Ophthalmol. 142 (2006) 660-668
119. Kaiser P.K., Brown D.M., Zhang K., Hudson H.L., Holz F.G., Shapiro H., Schneider S., and Acharya N.R. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am. J. Ophthalmol. 144 (2007) 850-857
120. Kaiserman I., McAllum P., Rootman D., and Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27 (2008) 142-147
121. Kapadia M.K., and Rubin P.A. The emerging use of TNF-alpha inhibitors in orbital inflammatory disease. Int. Ophthalmol. Clin. 46 (2006) 165-181
122. Kaushik V.V., and Moots R.J. CDP-870 (certolizumab) in rheumatoid arthritis. Expert Opin. Biol. Ther. 5 (2005) 601-606
123. Kazi A.A., Kivilcim M., Peyman G.A., Khan P., and Trost L. Intravitreal toxicity of infliximab. Investig. Ophthalmol. Vis. Sci. 47 (2006) E-Abstract 4298
124. Kim H., Csaky K.G., Chan C.C., Bungay P.M., Lutz R.J., Dedrick R.L., Yuan P., Rosenberg J., Grillo-Lopez A.J., Wilson W.H., and Robinson M.R. The pharmacokinetics of rituximab following an intravitreal injection. Exp. Eye Res. 82 (2006) 760-766
125. Kim T.I., Kim S.W., Kim S., Kim T., and Kim E.K. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 27 (2008) 349-352
126. Kim I., Ryan A.M., Rohan R., Amano S., Agular S., Miller J.W., and Adamis A.P. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Investig. Ophthalmol. Vis. Sci. 40 (1999) 2115-2121
127. Kipriyanov S.M., and Le Gall F. Generation and production of engineered antibodies. Mol. Biotechnol. 26 (2004) 39-60
128. Kitzmann A.S., Pulido J.S., Mohney B.G., Baratz K.H., Grube T., Marler R.J., Donaldson M.J., O'Neill B.P., Johnston P.B., Johnson K.M., Dixon L.E., Salomao D.R., and Cameron J.D. Intraocular use of rituximab. Eye 21 (2007) 1524-1527
129. Kivilcim M., Peyman G.A., Kazi A.A., Dellacroce J., Ghobrial R.N., and Monzano R. Intravitreal toxicity of high-dose etanercept. J. Ocul. Pharmacol. Ther. 23 (2007) 57-62
130. Klender B., and Sheardown H. Growth factors in the anterior segment: role in tissue maintenance wound healing and ocular pathology. Exp. Eye Res. 79 (2004) 677-688
131. Klettner A., and Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Investig. Ophthalmol. Vis. Sci. 49 (2008) 4523-4527
132. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
133. Kon C.H., Occleston N.L., Aylward G.W., and Khaw P.T. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Investig. Ophthalmol. Vis. Sci. 40 (1999) 705-712
134. Kriechbaum K., Michels S., Prager F., Georgopoulos M., Funk M., Geitzenauer W., and Schmidt-Erfurth U. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br. J. Ophthalmol. 92 (2008) 518-522
135. Krzystolik M.G., Afshari M.A., Adamis A.P., Gaudreault J., Gragoudas E.S., Michaud N.A., Li W., Connolly E., O'Neill C.A., and Miller J.W. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol. 120 (2002) 338-346
136. Kukk E., Lymboussaki A., Taira S., Kaipainen A., Jeltsch M., Joukov V., and Alitalo K. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122 (1996) 3829-3837
137. Lanthier N., Parc C., Scavennec R., Dhôte R., Brézin A.P., and Guillevi L. Infliximab in the treatment of posterior uveitis in Behcet's disease. Long term follow up in four patients. Presse. Med. 23 34 (2005) 916-918
138. Leonardi A., Brun P., Tavolato M., Plebani M., Abatangelo G., and Secchi A.G. Tumor necrosis factor-alpha (TNF-alpha) in seasonal allergic conjunctivitis and vernal keratoconjunctivitis. Eur. J. Ophthalmol. 13 (2003) 606-610
139. Li Z., Burns A.R., and Smith C.W. Lymphocyte function-associated antigen-1-dependent inhibition of corneal wound healing. Am. J. Pathol. 169 (2006) 1590-1600
140. Lim L., Suhler E.B., and Smith J.R. Biologic therapies for inflammatory eye disease. Clin. Exp. Ophthalmol. 34 (2006) 365-374
141. Limb G.A., Hollifield R.D., Webster L., Charteris D.G., and Chignell A.H. Soluble TNF receptors in vitreoretinal proliferative disease. Investig. Ophthalmol. Vis. Sci. 42 (2001) 1586-1591
142. Limb G.A., Soomro H., Janikoun S., Hollifield R.D., and Shilling J. Evidence for control of tumour necrosis factor-alpha (TNF-alpha) activity by TNF receptors in patients with proliferative diabetic retinopathy. Clin. Exp. Immunol. 115 (1999) 409-414
143. Lindstedt E.W., Baarsma G.S., Kuijpers R.W., and van Hagen P.M. Anti-TNF-alpha therapy for sight threatening uveitis. Br. J. Ophthalmol. 89 (2005) 533-536
144. Loizos N., Xu Y., Huber J., Liu M., Lu D., Finnerty B., Rolser R., Malikzay A., Persaud A., Corcoran E., Deevi D.S., Balderes P., Bassi R., Jimenez X., Joynes C.J., Mangalampalli V.R., Steiner P., Tonra J.R., Wu Y., Pereira D.S., Zhu Z., Ludwig D.L., Hicklin D.J., Bohlen P., Witte L., and Kussie P. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol. Cancer 4 (2005) 369-379
145. Lonberg N. Human antibodies from transgenic animals. Nat. Biotechnol. 23 (2005) 1117-1125
146. Lüke M., Warga M., Ziemssen F., Gelisken F., Grisanti S., Schneider T., Lüke C., Partsch M., Bartz-Schmidt K.U., Szurman P., and Tuebingen Bevacizumab Study Group. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br. J. Ophthalmol. 90 (2006) 1178-1182
147. Luthra S., Narayanan R., Marques L.E., Chwa M., Kim D.W., Dong J., Seigel G.M., Neekhra A., Gramajo A.L., Brown D.J., Kenney M.C., and Kuppermann B.D. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 26 (2006) 512-518
148. Luttun A., Tjwa M., and Carmeliet P. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann. N.Y. Acad. Sci. 979 (2002) 80-93
149. Lux A., Llacer H., Heussen F.M., and Joussen A.M. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br. J. Ophthalmol. 91 (2007) 1318-1322
150. Lymboussaki A., Partanen T.A., Olofsson B., Thomas-Crusells J., Fletcher C.D., de Waal R.M., Kaipainen A., and Alitalo K. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am. J. Pathol 153 (1998) 395-403
151. MacEwan D.J. TNF ligands and receptors - a matter of life and death. Br. J. Pharmacol. 135 (2002) 855-875
152. Macías I., García-Pérez S., Ruiz-Tudela M., Medina F., Chozas N., and Girón-González J.A. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis. J. Rheumatol. 32 (2005) 2102-2108
153. Madhusudhana K.C., Hannan S.R., Williams C.P., Goverdhan S.V., Rennie C., Lotery A.J., Luff A.J., and Newsom R.S. Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. Br. J. Ophthalmol. 91 (2007) 1716-1717
154. Mandal S., Garg S., Venkatesh P., Mithal C., Vohra R., and Mehrotra A. Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization. Arch. Ophthalmol. 125 (2007) 1487-1492
155. Manzano R.P., Peyman G.A., Khan P., Carvounis P.E., Kivilcim M., Ren M., Lake J.C., and Chévez-Barrios P. Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br. J. Ophthalmol. 91 (2007) 804-807
156. Manzano R.P., Peyman G.A., Khan P., and Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26 (2006) 257-261
157. Manzano R.P., Peyman G.A., Carvounis P.E., Kivilcim M., Khan P., Chevez-Barrios P., and Takahashi W. Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch. Clin. Exp. Ophthalmol. 246 (2008) 907-911
158. Markomichelakis N.N., Theodossiadis P.G., Pantelia E., Papaefthimiou S., Theodossiadis G.P., and Sfikakis P.P. Infliximab for chronic cystoid macular edema associated with uveitis. Am. J. Ophthalmol. 138 (2004) 648-650
159. Markomichelakis N.N., Theodossiadis P.G., and Sfikakis P.P. Regression of neovascular age-related macular degeneration following infliximab therapy. Am. J. Ophthalmol. 139 (2005) 537-540
160. Mathews M.K., Merges C., McLeod D.S., and Lutty G.A. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 38 (1997) 2729-2741
161. Matsumoto Y., Freund K.B., Peiretti E., Cooney M.J., Ferrara D.C., and Yannuzzi L.A. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina 27 (2007) 426-431
162. McDermott M.F. TNF and TNFR biology in health and disease. Cell. Mol. Biol. 47 (2001) 619-635
163. McKinnon S.J. Glaucoma: ocular Alzheimer's disease?. Front. Biosci. 8 (2003) 1140-1156
164. Miller J.W. Vascular endothelial growth factor and ocular neovascularization. Am. J. Pathol. 151 (1997) 13-23
165. Mead A.L., Wong T.T., and Cordeiro M.F. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Investig. Ophthalmol. Vis. Sci. 44 (2003) 3394-3401
166. Melichar B., and Nemcova I. Eye complications of cetuximab therapy. Eur. J. Cancer Care (Engl.) 16 (2007) 439-443
167. Meyer, C.H., Scholl, H.P., Eter, N., Helb, H.M., Holz, F.G. Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol., in press.
168. Moshfeghi A.A., Rosenfeld P.J., Puliafito C.A., Michels S., Marcus E.N., Lenchus J.D., and Venkatraman A.S. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113 (2006) 1-12
169. Murphy C.C., Ayliffe W.H., Booth A., Makanjuola D., Andrews P.A., and Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111 (2004) 352-356
170. Nakamura S., and Ohno S. Anti-tumor necrosis factor alpha antibody in the treatment of Behcet's disease. Int. Ophthalmol. Clin. 45 (2005) 179-189
171. Nakamura Y., Sotozono C., and Kinoshita S. The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis. Exp. Eye Res. 72 (2001) 511-517
172. Nakazawa T., Matsubara A., Noda K., Hisatomi T., She H., Skondra D., Miyahara S., Sobrin L., Thomas K.L., Chen D.F., Grosskreutz C.L., Hafezi-Moghadam A., and Miller J.W. Characterization of cytokine responses to retinal detachment in rats. Mol. Vis. 12 (2006) 867-878
173. Nanda S., and Bathon J.M. Etanercept: a clinical review of current and emerging indications. Expert Opin. Pharmacother. 5 (2004) 1175-1186
174. Nestorov I. Clinical pharmacokinetics of tumor necrosis factor antagonists. J. Rheumatol. Suppl. 74 (2005) 13-18
175. Neufeld G., Cohen T., Gengrinovitch S., and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13 (1999) 9-22
176. Nguyen Q.D., Shah S., Tatlipinar S., Do D.V., Anden E.V., and Campochiaro P.A. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br. J. Ophthalmol. 89 (2005) 1368-1370
177. Nguyen Q.D., Tatlipinar S., Shah S.M., Haller J.A., Quinlan E., Sung J., Zimmer-Galler I., Do D.V., and Campochiaro P.A. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am. J. Ophthalmol. 142 (2006) 961-969
178. Niccoli L., Nannini C., Benucci M., Chindamo D., Cassarà E., Salvarani C., Cimino L., Gini G., Lenzetti I., and Cantini F. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology 46 (2007) 1161-1164
179. Nishijima K., Ng Y.S., Zhong L., et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 171 (2007) 53-67
180. Ohno S., Nakamura S., Hori S., Shimakawa M., Kawashima H., Mochizuki M., Sugita S., Ueno S., Yoshizaki K., and Inaba G. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J. Rheumatol. 31 (2004) 1362-1368
181. Okada A.A. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul. Immunol. Inflamm. 13 (2005) 335-351
182. Olofsson B., Pajusola K., Kaipainen A., von Euler G., Joukov V., Saksela O., Orpana A., Pettersson R.F., Alitalo K., and Eriksson U. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 2576-2581
183. Olson J.L., Courtney R.J., and Mandava N. Intravitreal infliximab and choroidal neovascularization in an animal model. Arch. Ophthalmol. 125 (2007) 1221-1224
184. Ozaki H., Seo M.S., Ozaki K., Yamada H., Yamada E., Okamoto N., Hofmann F., Wood J.M., and Campochiaro P.A. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am. J. Pathol. 156 (2000) 697-707
185. Pessler F., Monash B., Rettig P., Forbes B., Kreiger P.A., and Cron R.Q. Sjogren syndrome in a child: favorable response of the arthritis to TNFalpha blockade. Clin. Rheumatol. 25 (2006) 746-748
186. Peters S., Heiduschka P., Julien S., Ziemssen F., Fietz H., Bartz-Schmidt K.U., Schraermeyer U., and Tübingen Bevacizumab Study Group. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am. J. Ophthalmol. 143 (2007) 995-1002
187. Peterson N.C. Advances in monoclonal antibody technology: genetic engineering of mice, cells, and immunoglobulins. ILAR J. 46 (2005) 314-319
188. Pfeffer B.A., Flanders K.C., Guerin C.J., Danielpour D., and Anderson D.H. Transforming growth factor beta 2 is the predominant isoform in the neural retina, retinal pigment epithelium-choroid and vitreous of the money eye. Exp. Eye Res. 59 (1994) 323-333
189. Philipp W., Speicher L., and Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Investig. Ophthalmol. Vis. Sci. 41 (2000) 2514-2522
190. Prager F., Michels S., Geitzenauer W., and Schmidt-Erfurth U. Choroidal neovascularization secondary to Sorsby fundus dystrophy treated with systemic bevacizumab (Avastin). Acta Ophthalmol. Scand. 85 (2007) 904-906
191. Priglinger S.G., Wolf A.H., Kreutzer T.C., Kook D., Hofer A., Strauss R.W., Alge C.S., Kunze C., Haritoglou C., and Kampik A. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 27 (2007) 1004-1012
192. Quiroz-Mercado H., Martinez-Castellanos M.A., Hernandes-Rojas M.L., Salazar-Teran N., and Chan R.V.P. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 28 (2008) S19-S25
193. Rajaraman R.T., Kimura Y., Li S., Haines K., and Chu D.S. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 113 (2006) 308-314
194. Rayner S.A., King W.J., Comer R.M., Isaacs J.D., Hale G., George A.J., and Larkin D.F. Local bioactive tumour necrosis factor (TNF) in corneal allotransplantation. Clin. Exp. Immunol. 122 (2000) 109-116
195. Rau R. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann. Rheum. Dis. 2 (2002) 70-73
196. Reichert J.M. Monoclonal antibodies in the clinic. Nat. Biotechnol. 19 (2001) 819-822
197. Rubin P.A., and Foster C.S. Etiology and management of idiopathic orbital inflammation. Am J. Ophthalmol. 138 (2004) 1041-1043
198. Ruiz-Moreno J.M., Montero J.A., Lugo F., Amat P., and Staicu C. Intravitreal bevacizumab in recurrent diabetic vitreous haemorrhage after vitrectomy. Acta Ophthalmol. Scand. (Sep 21, 2007)
199. Reichert J.M., and Valge-Archer V.E. Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov. 6 (2007) 349-356
200. Reiff A., Takei S., Sadeghi S., Stout A., Shaham B., Bernstein B., Gallagher K., and Stout T. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 44 (2001) 1411-1415
201. Richards J.C., Tay-Kearney M.L., Murray K., and Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin. Exp. Ophthalmol. 33 (2005) 461-468
202. Rinaldi M., Dell'Omo R., Romano M.R., Chiosi F., Cipollone U., and Costagliola C. Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks. Arch. Ophthalmol. 125 (2007) 1422-1423
203. Rodrigues E.B., Shiroma H., Meyer C.H., Maia M., and Farah M.E. Metrorrhagia after intravitreal injection of bevacizumab. Acta Ophthalmol. Scand. (Jul 23, 2007)
204. Rosenbaum J.T., and Boney R.S. Failure to inhibit endotoxin-induced uveitis with antibodies that neutralize tumor necrosis factor. Reg. Immunol. 5 (1993) 299-303
205. Rosenbaum J.T., and Smith J.R. Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin. Exp. Rheumatol. 20 (2002) S143-S145
206. Rosenfeld P.J. Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues. Br. J. Ophthalmol. 91 (2007) 128-130
207. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., and Kim R.Y. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355 (2006) 1419-1431
208. Rosenfeld P.J., Rich R.M., and Lalwani G.A. Ranibizumab: phase III clinical trial results. Ophthalmol. Clin. North Am. 19 (2006) 361-372
209. Rosenfeld P.J., Schwartz S.D., Blumenkranz M.S., Miller J.W., Haller J.A., Reimann J.D., Greene W.L., and Shams N. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112 (2005) 1048-1053
210. Sakaguchi H., Ikuno Y., Gomi F., Kamei M., Sawa M., Tsujikawa M., Oshima Y., Kusaka S., and Tano Y. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br. J. Ophthalmol. 91 (2007) 161-165
211. Salvi M., Vannucchi G., Campi I., Rossi S., Bonara P., Sbrozzi F., Guastella C., Avignone S., Pirola G., Ratiglia R., and Beck-Peccoz P. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur. J. Endocrinol. 154 (2006) 511-517
212. Santos Lacomba M., Marcos Martin C., Gallardo Galera J.M., Gómez Vidal M.A., Rubin P.A., and Foster C.S. Etiology and management of idiopathic orbital inflammation. Am. J. Ophthalmol. 138 (2004) 1041-1043
213. Santos Lacomba M., Marcos Martín C., Gallardo Galera J.M., Gómez Vidal M.A., Collantes Estévez E., Ramírez Chamond R., and Omar M. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 33 (2001) 251-255
214. Saurenmann R.K., Levin A.V., Rose J.B., Parker S., Rabinovitch T., Tyrrell P.N., Feldman B.M., Laxer R.M., Schneider R., and Silverman E.D. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology 45 (2006) 982-989
215. Scallon B., Cai A., Solowski N., Rosenberg A., Song X.Y., Shealy D., and Wagner C. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. 301 (2002) 418-426
216. Schmeling H., and Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology 44 (2005) 1008-1011
217. Scott D.L., and Kingsley G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med. 355 (2006) 704-712
218. Schulz M.W., Chamberlain C.G., and McAvoy J.W. Inhibition of transforming growth factor-beta-induced cataractous changes in lens explants by ocular media and alpha 2-macroglobulin. Investig. Ophthalmol. Vis. Sci. 37 (1996) 1509-1519
219. Seo M.S., Okamoto N., Vinores M.A., Vinores S.A., Hackett S.F., Yamada H., Yamada E., Derevjanik N.L., LaRochelle W., Zack D.J., and Campochiaro P.A. Photoreceptor-specific expression of PDGF-B results in traction retinal detachment. Am. J. Pathol. 157 (2000) 995-1005
220. Sfikakis P.P., Kaklamanis P.H., Elezoglou A., Katsilambros N., Theodossiadis P.G., Papaefthimiou S., and Markomichelakis N. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann. Intern. Med. 140 (2004) 404-406
221. Sfikakis P.P., Markomichelakis N., Theodossiadis G.P., Grigoropoulos V., Katsilambros N., and Theodossiadis P.G. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care 28 (2005) 445-447
222. Sfikakis P.P., Theodossiadis P.G., Katsiari C.G., Kaklamanis P., and Markomichelakis N.N. Effect of inxliximab on sight-threatening panuveitis in Behcet's disease. Lancet 358 (2001) 295-296
223. Shahar J., Avery R.L., Heilweil G., Barak A., Zemel E., Lewis G.P., Johnson P.T., Fisher S.K., Perlman I., and Loewenstein A. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26 (2006) 262-269
224. Shen B.Q. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein C signaling pathway. J. Biol. Chem. 274 (1999) 33057-33063
225. Shi X., Semkova I., Muther P.S., Dell S., Kociok N., and Joussen A.M. Inhibition of TNF-alpha reduces laser-induced choroidal neovascularization. Exp. Eye Res. 83 (2006) 1325-1334
226. Shu S., Plautz G.E., Krauss J.C., and Chang A.E. Tumor immunology. JAMA 278 (1997) 1972-1981
227. Singh V.K., and Rai G. Cytokines in posterior uveitis: an update. Immunol. Res. 23 (2001) 59-74
228. Sippy B.D., Hofman F.M., Wright A.D., He S., Ryan S.J., and Hinton D.R. Soluble tumor necrosis factor receptors are present in human vitreous and shed by retinal pigment epithelial cells. Exp. Eye Res. 63 (1996) 311-317
229. Sivakumar V., Zhang Y., Ling E.A., Foulds W.S., and Kaur C. Insulin-like growth factors, angiopoietin-2, pigment epithelium-derived growth factor in the hypoxic retina. J. Neurosci. Res. 86 (2008) 702-711
230. Smith J.R., Hart P.H., and Williams K.A. Basic pathogenic mechanisms operating in experimental models of acute anterior uveitis. Immunol. Cell Biol. 76 (1998) 497-512
231. Smith J.R., Levinson R.D., Holland G.N., Jabs D.A., Robinson M.R., Whitcup S.M., and Rosenbaum J.T. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 45 (2001) 252-257
232. Sondell M., Sundler F., and Kanje M. Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor. Eur. J. Neurosci. 12 (2000) 4243-4254
233. Song, W.K., Min, Y.H., Kim, Y.R., Lee, S.C. Cytomegalovirus retinitis after hematopoietic stem cell transplantation with alemtuzumab. Ophthalmology, in press.
234. Spitzer M.S., Yoeruek E., Sierra A., Wallenfels-Thilo B., Schraermeyer U., Spitzer B., Bartz-Schmidt K.U., and Szurman P. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen), and ranibizumab (Lucentis) on different ocular cells. Graefes Arch. Clin. Exp. Ophthalmol. 245 (2007) 1837-1842
235. Stone E.M. A very effective treatment for neovascular macular degeneration. N. Engl. J. Med. 355 (2006) 1493-1495
236. Suhler E.B., Smith J.R., Wertheim M.S., Lauer A.K., Kurz D.E., Pickard T.D., and Rosenbaum J.T. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch. Ophthalmol. 123 (2005) 903-912
237. Tai T.L., O'Rourke K.P., McWeeney M., et al. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology 41 (2002) 951-952
238. Takagi H., King G.L., Robinson G.S., Ferrara N., and Aiello L.P. Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells. Invest. Ophthalmol. Vis. Sci. 37 (1996) 2165-2176
239. Teillaud J.L., Desaymard C., Giusti A.M., Haseltine B., Pollock R.R., Yelton D.E., Rosenbaum J.T., and Smith J.R. Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin. Exp. Rheumatol. 20 (2002) S143-S145
240. Tezel G., Li L.Y., Patil R.V., and Wax M.B. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Investig. Ophthalmol. Vis. Sci. 42 (2001) 1787-1794
241. Tezel G., Yang X., Yang J., and Wax M.B. Role of tumor necrosis factor receptor-1 in the death of retinal ganglion cells following optic nerve crush injury in mice. Brain Res. 996 (2004) 202-212
242. Thakker G.D., Hajjar D.P., Muller W.A., and Rosengart T.K. The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J. Biol. Chem. 274 (1999) 10002-10007
243. Theodossiadis P.G., Markomichelakis N.N., and Sfikakis P.P. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 27 (2007) 399-413
244. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., and Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117 (2008) 244-279
245. Tsilimbaris M.K., Panagiotoglou T.D., Charisis S.K., Anastasakis A., Krikonis T.S., and Christodoulakis E. The use of intravitreal etanercept in diabetic macular oedema. Semin. Ophthalmol. 22 (2007) 75-79
246. Tugal-Tutkun I., Mudun A., Urgancioglu M., Kamali S., Kasapoglu E., Inanc M., and Gül A. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum. 52 (2005) 2478-2484
247. Tuli S.S., Liu R., Chen C., Blalock T.D., Goldstein M., and Schultz G.S. Immunohistochemical localization of EFG, TGF-alpha, TGF-alpha, and their receptors in rat corneas during healing of excimer laser ablation. Curr. Eye Res. 31 (2006) 709-719
248. Valamanesh F., Torriglia A., Savoldelli M., Gandolphe C., Jeanny J., BenEzra D., and Behar-Cohen F. Glucocorticoids induce retinal toxicity through mechanisms mainly associated with paraptosis. Mol. Vis. 13 (2007) 1746-1757
249. Vazquez-Cobian L.B., Flynn T., and Lehman T.J. Adalimumab therapy for childhood uveitis. J. Pediatr. 149 (2006) 572-575
250. Verheul H.M.W., and Pinedo H.M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat. Rev. Cancer 7 (2007) 75-85
251. Vitetta E.S., and Ghetie V.F. Immunology: considering therapeutic antibodies. Science 313 (2006) 308-309
252. de Vos A.F., Klaren V.N., and Kijlstra A. Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat. Investig. Ophthalmol. Vis. Sci. 35 (1994) 3873-3883
253. Waldmann T.A. Monoclonal antibodies in diagnosis and therapy. Science 252 (1991) 1657-1662
254. Wajant H., Henkler F., and Scheurich P. The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. Cell Signal. 13 (2001) 389-400
255. Watanabe H., Ohashi Y., Kinoshita S., Manabe R., and Ohshiden K. Distribution of epidermal growth factor in rat ocular and periocular tissues. Graefes Arch. Clin. Exp. Ophthalmol. 231 (1993) 228-232
256. Wechsler B., Sable-Fourtassou R., Bodaghi B., Huong D.L., Cassoux N., Badelon I., Fain O., LeHoang P., and Piette J.C. Infliximab in refractory uveitis due to Behcet's disease. Clin. Exp. Rheumatol. 22 (2004) S14-S16
257. Weiner L.M. Fully human therapeutic monoclonal antibodies. J. Immunother. 29 (2006) 1-9
258. Weisman M.H., Moreland L.W., Furst D.E., Weinblatt M.E., Keystone E.C., Paulus H.E., Teoh L.S., Velagapudi R.B., Noertersheuser P.A., Granneman G.R., Fischkoff S.A., and Chartash E.K. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin. Ther. 25 (2003) 1700-1721
259. Wertheim M.S., Ross A.H., and Tole D.M. The use of Campath in severe peripheral ulcerative keratitis associated with Wegener's granulomatosis. Eye 20 (2006) 1453-1454
260. Whitcup S.M., Hikita N., Shirao M., Miyasaka M., Tamatani T., Mochizuki M., Nussenblatt R.B., and Chan C.C. Monoclonal antibodies against CD54 (ICAM-1) and CD11a (LFA-1) prevent and inhibit endotoxin-induced uveitis. Exp. Eye Res. 60 (1995) 597-601
261. Wilkinson-Berka J.L., Wraight C., and Werther G. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. Curr. Med. Chem. 27 (2006) 3307-3317
262. Wilson S.E., Liu J.J., and Mohan R.R. Stromal-epithelial interactions in the cornea. Prog. Retin. Eye Res. 18 (1999) 293-309
263. Wilson M.W., Shergy W.J., and Haik B.G. Infliximab in the treatment of recalcitrant idiopathic orbital inflammation. Ophthal. Plast. Reconstr. Surg. 20 (2004) 381-383
264. Witmer A.N., Dai J., Weich H.A., Vrensen G.F., and Schlingemann R.O. Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J. Histochem. Cytochem. 50 (2002) 767-777
265. Witmer A.N., Vrensen G.F., Van Noorden C.J., and Schlingemann R.O. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin. Eye Res. 22 (2003) 1-29
266. Wong L.J., Desai R.U., Jain A., Feliciano D., Moshfeghi D.M., Sanislo S.R., and Blumenkranz M.S. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina. 28 (2008) 1151-1158
267. Wu L., Martínez-Castellanos M.A., Quiroz-Mercado H., Arevalo J.F., Berrocal M.H., Farah M.E., Maia M., Roca J.A., Rodriguez F.J., and for the Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch. Clin. Exp. Ophthalmol. 246 (2008) 81-87
268. Yazdani S., Hendi K., and Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J. Glaucoma 16 (2007) 437-439
269. Zack D.J., and Scharff M.D. Monoclonal antibodies reveal the structural basis of antibody diversity. Science 222 (1983) 721-726
270. Zhao B., Smith G., Cai J., Ma A., and Boulton M.E. VEGF-C promotes survival of retinal vascular endothelial cells via VEGFR-2. Br. J. Ophthalmol. 91 (2007) 538-545
271. Zheng M., Deshpande S., Lee S., Ferrara N., and Rouse B.T. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J. Virol. 75 (2001) 9828-9835
272. Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J. Clin. Pharmacol. 45 (2005) 490-497